Literature DB >> 16972082

Electroretinographic abnormalities in multiple sclerosis: possible role for retinal autoantibodies.

Farzin Forooghian1, Melanie Sproule, Carol Westall, Lynn Gordon, Guy Jirawuthiworavong, Kaori Shimazaki, Paul O'Connor.   

Abstract

BACKGROUND: Multiple sclerosis (MS) has been associated with inflammation of the uveal tract, suggesting an immunological link between the uvea and central nervous system (CNS) in this disease. The retina is embryologically derived from the CNS, and it is conceivable that retinal antigens may also be recognized by the immune system in MS. Electroretinographic abnormalities, as well as retinal autoantibodies, have previously been described in MS. We performed this study to further explore the possibility of retinal autoimmunity in MS.
METHODS: Thirty-four patients with clinically definite MS and thirty-seven healthy controls were recruited. All patients and controls had standard electroretinographic (ERG) testing done, as well as a brightflash ERG protocol to isolate rod photoreceptor function. Patient and control sera were analyzed for the presence of antiretinal antibodies using Western blot techniques.
RESULTS: We found statistically significant differences between MS patients and controls in four ERG parameters. In the MS group, implicit times of the rod-cone b-wave response, cone b-wave response, and rod photoreceptor response were increased. The amplitudes of the photopic oscillatory potentials were reduced in the MS group. Patients with the highest titres of retinal autoantibodies had delayed rod-cone b-wave implicit times and diminished photopic oscillatory potential amplitudes.
CONCLUSIONS: We report ERG evidence of retinal dysfunction in patients with MS. We also report the first use of the brightflash ERG protocol in MS, which demonstrated rod photoreceptor dysfunction. Patients with the highest antiretinal antibody titres had abnormal ERG recordings. Retinal autoimmunity is a possible explanation for these observed ERG abnormalities in MS patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16972082     DOI: 10.1007/s10633-006-9022-0

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  37 in total

1.  The electroretinogram in multiple sclerosis and demyelinating optic neuritis.

Authors:  D Papakostopoulos; F Fotiou; J C Hart; N K Banerji
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1989 Jan-Feb

2.  Cancer-associated retinopathy in a patient with advanced epithelial ovarian carcinoma.

Authors:  J P Harmon; V A Purvin; J Guy; N Aptsiauri; G P Sutton
Journal:  Gynecol Oncol       Date:  1999-06       Impact factor: 5.482

3.  Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies.

Authors:  Richard G Weleber; Robert C Watzke; William T Shults; Karmen M Trzupek; John R Heckenlively; Robert A Egan; Grazyna Adamus
Journal:  Am J Ophthalmol       Date:  2005-05       Impact factor: 5.258

4.  Electroretinographic abnormalities and advanced multiple sclerosis.

Authors:  J P Gills
Journal:  Invest Ophthalmol       Date:  1966-12

5.  Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa.

Authors:  J R Heckenlively; B L Jordan; N Aptsiauri
Journal:  Am J Ophthalmol       Date:  1999-05       Impact factor: 5.258

6.  Flash electroretinogram abnormalities in patients with clinically definite multiple sclerosis.

Authors:  S G Coupland; T H Kirkham
Journal:  Can J Neurol Sci       Date:  1982-08       Impact factor: 2.104

7.  Blood-retinal barrier breakdown in retinitis pigmentosa: light and electron microscopic immunolocalization.

Authors:  S A Vinores; M Küchle; N L Derevjanik; J D Henderer; J Mahlow; W R Green; P A Campochiaro
Journal:  Histol Histopathol       Date:  1995-10       Impact factor: 2.303

8.  Retinal antigens are recognized by antibodies present in sera of patients with multiple sclerosis.

Authors:  Wojciech A Gorczyca; Maria Ejma; Danuta Witkowska; Marta Misiuk-Hojło; Marianna Kuropatwa; Małgorzata Mulak; Stanisław Szymaniec
Journal:  Ophthalmic Res       Date:  2004 Mar-Apr       Impact factor: 2.892

9.  Multiple sclerosis associated with uveitis in two large clinic-based series.

Authors:  V Biousse; C Trichet; E Bloch-Michel; E Roullet
Journal:  Neurology       Date:  1999-01-01       Impact factor: 9.910

10.  Neurological disease activity in multiple sclerosis patients with periphlebitis retinae.

Authors:  T Engell
Journal:  Acta Neurol Scand       Date:  1986-02       Impact factor: 3.209

View more
  17 in total

1.  In vivo assessment of retinal neuronal layers in multiple sclerosis with manual and automated optical coherence tomography segmentation techniques.

Authors:  Michaela A Seigo; Elias S Sotirchos; Scott Newsome; Aleksandra Babiarz; Christopher Eckstein; E'tona Ford; Jonathan D Oakley; Stephanie B Syc; Teresa C Frohman; John N Ratchford; Laura J Balcer; Elliot M Frohman; Peter A Calabresi; Shiv Saidha
Journal:  J Neurol       Date:  2012-03-15       Impact factor: 4.849

Review 2.  The need for standardization of antiretinal antibody detection and measurement.

Authors:  Farzin Forooghian; Ian M Macdonald; John R Heckenlively; Elise Héon; Lynn K Gordon; John J Hooks; Barbara Detrick; Robert B Nussenblatt
Journal:  Am J Ophthalmol       Date:  2008-07-30       Impact factor: 5.258

3.  Electroretinogram findings in unilateral optic neuritis.

Authors:  Clare L Fraser; Graham E Holder
Journal:  Doc Ophthalmol       Date:  2011-10-30       Impact factor: 2.379

4.  Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration.

Authors:  Ari J Green; Stephen McQuaid; Stephen L Hauser; Ingrid V Allen; Roy Lyness
Journal:  Brain       Date:  2010-04-21       Impact factor: 13.501

5.  Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis.

Authors:  Shiv Saidha; Elias S Sotirchos; Jiwon Oh; Stephanie B Syc; Michaela A Seigo; Navid Shiee; Chistopher Eckstein; Mary K Durbin; Jonathan D Oakley; Scott A Meyer; Teresa C Frohman; Scott Newsome; John N Ratchford; Laura J Balcer; Dzung L Pham; Ciprian M Crainiceanu; Elliot M Frohman; Daniel S Reich; Peter A Calabresi
Journal:  JAMA Neurol       Date:  2013-01       Impact factor: 18.302

6.  Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study.

Authors:  Shiv Saidha; Elias S Sotirchos; Mohamed A Ibrahim; Ciprian M Crainiceanu; Jeffrey M Gelfand; Yasir J Sepah; John N Ratchford; Jiwon Oh; Michaela A Seigo; Scott D Newsome; Laura J Balcer; Elliot M Frohman; Ari J Green; Quan D Nguyen; Peter A Calabresi
Journal:  Lancet Neurol       Date:  2012-10-04       Impact factor: 44.182

7.  Comparison of point estimates and average thicknesses of retinal layers measured using manual optical coherence tomography segmentation for quantification of retinal neurodegeneration in multiple sclerosis.

Authors:  Elias S Sotirchos; Michaela A Seigo; Peter A Calabresi; Shiv Saidha
Journal:  Curr Eye Res       Date:  2012-09-06       Impact factor: 2.424

Review 8.  The afferent visual pathway: designing a structural-functional paradigm of multiple sclerosis.

Authors:  Fiona Costello
Journal:  ISRN Neurol       Date:  2013-11-06

9.  Inner nuclear layer thickening is inversley proportional to retinal ganglion cell loss in optic neuritis.

Authors:  Megha Kaushik; Chen Yu Wang; Michael H Barnett; Raymond Garrick; John Parratt; Stuart L Graham; Prema Sriram; Con Yiannikas; Alexandr Klistorner
Journal:  PLoS One       Date:  2013-10-03       Impact factor: 3.240

10.  Relationship between optical coherence tomography and electrophysiology of the visual pathway in non-optic neuritis eyes of multiple sclerosis patients.

Authors:  Prema Sriram; Chenyu Wang; Con Yiannikas; Raymond Garrick; Michael Barnett; John Parratt; Stuart L Graham; Hemamalini Arvind; Alexander Klistorner
Journal:  PLoS One       Date:  2014-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.